|
|
4105 E Madison St, Suite 320
Seattle, WA 98122 USA
phone:206.325.6086
fax:206.325.6087
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.atossagenetics.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Healthcare company focused on the development of novel cellular and molecular diagnostics |
|
| Management |
| Dr. Steven C. Quay, Chairman of the Board and CEO; Dr. Shu-Chih Chen, Chief Scientific Officer and Director; John Barnhart, Director |
| |
|
|
| |
|
| Keywords |
| breast cancer, oncology, womens\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\' health, mammogram |
|
|
|
|
|
|
| Description |
|
At Atossa Genetics there is only one mission: to help women, together with their healthcare providers, manage their health and well being by providing information about research, clinical trials, and best practices in breast health and medical care.
Atossa believes Nipple Aspirate Fluid (NAF) is a rich source of information about an individual woman\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s breast health. By focusing exclusively AND ON NO OTHER MEDICAL CONDITIONS on every aspect of NAF collection, its direct transportation to our laboratory and its immediate analysis by our team of experts, the company believes it can provide complete, accurate, and timely information to help you in designing personal programs to:
maintain breast health;
intervene to lower the chance of developing breast cancer if you are identified at higher risk;
or help in the monitoring and tailoring of your breast cancer treatment program. |
|
| Products / Services |
The MASCT System is FDA cleared for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells. The MASCT System is a simple and reliable method for NAF collection. The MASCT System uses a hydrophilic (water seeking) membrane in contact with the nipple to wick fluid from the orifice of the ducts by capillary action during the cycles of negative pressure, thereby increasing the frequency of obtaining NAF in women. The MASCT has been awarded 14 US and international patents for aspects of this design.
In clinical testing, NAF samples were collected in 97% of women. NAF analysis is an objective assessment of a patient\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s breast health and can detect early cellular changes in the ducts. Regular assessment and tracking of cellular changes in the milk ducts, where most breast cancer begins, enables clinicians and patients to take control of breast health.
The MASCT System provides important benefits to both clinicians and patients.
For clinicians, the MASCT System provides a new assessment of breast health, NAF cytology and molecular diagnostic biomarkers. The routine use of the MASCT System during annual physical exams and mammograms use creates documentation that can be helpful over the years to observe changes and trends. NAF collection is simple, takes about 5-minutes per breast and can be done by a nurse or physician assistant, since it requires no specialized training.
For patients, it is noninvasive, painless, and takes about 10 minutes. It fits easily into the schedule before mammography, the annual Pap smear exams, or during a routine wellness or health checkup.
Important: The MASCT System test cannot exclude breast cancer and is not a substitute for other clinical screening tests, such as mammography and clinical breast exam.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members